Skip to main content
GutCited

Lactobacillus rhamnosus GG için Irritable Bowel Syndrome (IBS)

B

Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Sonuç

Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms Etki: None None

Popülasyon: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial 3 weeks Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None vs: Placebo Outcome: Pain outcomes Etki: None None

Popülasyon: IBS patients

Systematic Review n=3
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic …
Dose: None vs: None Outcome: Abdominal pain frequency/intensity, constipation Etki: None None

Popülasyon: Children with FAPD or functional constipation

Systematic Review
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Dose: various probiotic strains vs: placebo Outcome: IBS symptom improvement in children Etki: LGG showed benefit in some studies None

Popülasyon: Children with IBS

Review
Probiotic Bacterial and Fungal Strains: Claims with Evidence.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: Various populations (probiotic claims review)

Review
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: IBD patients

Key Statistics

8

Çalışmalar

1200

Katılımcılar

Positive

B

Derece

Referenced Papers

Digestive diseases (Basel, … 2016 37 atıf
Journal of pediatric … 2016 19 atıf
Asia Pacific journal … 2006 45 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

Üst sınır: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Positive --
None 3 weeks Positive --
None -- Mixed 3
various probiotic strains -- Mixed --
None -- Mixed --
None -- Mixed --
None -- Mixed --
None 26.0 weeks Mixed --

En iyi alım zamanı: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

Bildirilen Yan Etkiler

  • Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • Rare reports of bacteremia in severely immunocompromised individuals
  • Occasional loose stools during adjustment period
  • Very rare: systemic infection in critically ill patients with central venous catheters

Bilinen Etkileşimler

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • Antifungals (no known interaction but may affect gut flora balance)

Tolere edilebilir üst alım: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with Irritable Bowel Syndrome (IBS)?
Based on 8 studies with 1,200 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus GG may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus GG should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 1,200 total participants. The overall direction of effect is positive.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.